BioPharm International-08-01-2014

Single-domain antibodies are emerging as credible alternatives due to their target specificity, high affinity, and cost-effective recombinant production.

Data analytic strategies can help companies capitalize on personalized medicine.

Defining best biopharmaceutical practices is necessary to ensure the safety of the supply chain.

FDA seeks high quality applications and products to facilitate approvals and reduce safety and supply problems.

Part II of this three-part series presents a roadmap to human error prevention.

Click the title above to open the BioPharm International August 2014 issue in an interactive PDF format.